The potential of AR-V7 as a therapeutic target

Takuma Uo,Stephen R. Plymate,Cynthia C. Sprenger
DOI: https://doi.org/10.1080/14728222.2018.1439016
IF: 6.797
2018-02-15
Expert Opinion on Therapeutic Targets
Abstract:INTRODUCTION: The androgen receptor variant AR-V7 is gaining attention as a potential predictive marker for as well as one of the resistance mechanisms to the most current anti-androgen receptor (AR) therapies in castration-resistant prostate cancer (CRPC). Accordingly, development of next-generation drugs that directly or indirectly target AR-V7 signaling is urgently needed. Areas covered: We review proposed mechanisms of drug resistance in relation to AR-V7 status, the mechanisms of generation of AR-V7, and its transcriptome, cistrome, and interactome. Pharmacological agents that interfere with these processes are being developed to counteract pan AR and AR-V7-specific signaling. Also, we address the current status of the preclinical and clinical studies targeting AR-V7 signaling. Expert opinion: AR-V7 is considered a true therapeutic target, however, it remains to be determined if AR-V7 is a principal driver or merely a bystander requiring heterodimerization with co-expressed full-length AR or other variants to drive CRPC progression. While untangling AR-V7 biology, multiple strategies are being developed to counteract drug resistance, including selective blockade of AR-V7 signaling as well as inhibition of pan-AR signaling. Ideally anti-AR therapies will be combined with agents preventing activation and enrichment of AR negative tumor cells that are otherwise depressed by AR activity axis.
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the potential of androgen receptor variant AR - V7 as a therapeutic target in castration - resistant prostate cancer (CRPC). Specifically, the paper focuses on the following aspects: 1. **Adaptive resistance mechanisms**: The paper explores the drug - resistance mechanisms related to the AR - V7 status, especially the role of AR - V7 in current anti - androgen receptor (AR) therapies. 2. **Generation mechanism of AR - V7**: The paper discusses in detail the generation mechanism of AR - V7, including its transcriptome, cis - regulatory elements (cistrome) and interactome. 3. **Drug intervention strategies**: The paper introduces the drugs being developed that can interfere with these processes to combat pan - AR and AR - V7 - specific signal transduction. 4. **Current status of clinical research**: The paper summarizes the progress of pre - clinical and clinical research on AR - V7 signal transduction at present. 5. **Future research directions**: The paper proposes future research directions, including the development of a new generation of treatment methods to deal with the new CRPC phenotypes that emerge and evolve under the selective pressure of pre - clinical test drugs. ### Summary of main content - **Background**: Prostate cancer often develops into castration - resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT). Although AR is still a key driver of CRPC progression, tumor cells re - activate AR signal transduction through multiple mechanisms, leading to resistance to existing anti - AR therapies. - **Role of AR - V7**: AR - V7 is an AR variant lacking a ligand - binding domain (LBD). Its expression is increased in CRPC and is considered one of the important mechanisms leading to resistance to existing anti - AR therapies. Therefore, AR - V7 is considered a potential predictive marker and therapeutic target. - **Generation mechanism**: The generation of AR - V7 involves multiple mechanisms, including abnormal alternative splicing, changes in RNA processing pathways, the involvement of long non - coding RNAs (lncRNAs), and genomic structure rearrangements (GSRs). - **Drug intervention**: To combat AR - V7 - mediated resistance, researchers are developing a variety of drugs, including drugs that directly or indirectly target AR - V7 signal transduction and drugs that inhibit pan - AR signal transduction. - **Clinical research**: At present, there are multiple pre - clinical and clinical studies exploring AR - V7 signal transduction, and the preliminary results show some promising results. - **Future prospects**: Although AR - V7 is considered an important target for the treatment of CRPC, further research is still needed to determine whether it is the main driver and how to effectively target AR - V7 to overcome resistance. Through these studies, the paper aims to provide a theoretical basis and experimental evidence for the development of new treatment methods to improve the treatment outcomes of CRPC patients.